AngioDynamics vs Artivion
ANGO and AORT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANGO and AORT compare
Artivion is the larger company, worth 1.9 times as much as AngioDynamics ($980M against $522M).
Artivion grew revenue faster over the last twelve months (14.0% versus 8.2% for AngioDynamics).
Artivion keeps more of each dollar of sales as profit, with a net margin of −3.7% compared with −10.1% at AngioDynamics.
AngioDynamics scores higher on the StockData Score (12 against 8 for Artivion), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANGO | AORT |
|---|---|---|
| Size and price | ||
| Market cap | $522M | $980M |
| Share price | $12.42 | $20.10 |
| Change, 1 year | 1.1% | −55.3% |
| Change, 5 years | −56.5% | 6.1% |
| Beta (5Y) | 0.34 | 1.16 |
| Employees | 632 | 1,800 |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 2 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 3 | 3 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.6× (better) | 2.0× |
| P/B | 3.2× | 2.2× (better) |
| EV/EBITDA | – | 34.8× |
| P/FCF | 362× | – |
| FCF yield | 0.28% (better) | −4.5% |
| Fair value | $13.24 | $15.71 |
| Margin of safety | 6.2% (better) | −28.0% |
| Growth | ||
| Revenue growth (TTM) | 8.2% | 14.0% (better) |
| Revenue growth, 5Y average | 1.9% | 11.8% (better) |
| Profitability | ||
| Gross margin | 55.7% | 63.3% (better) |
| Operating margin | −11.2% | 2.3% (better) |
| Net margin | −10.1% | −3.7% (better) |
| FCF margin | 0.44% (better) | −9.2% |
| Return on equity | −19.2% | −4.0% (better) |
| Return on invested capital | −21.4% | 1.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.81 (better) |
| Net debt / EBITDA | – | 8.47 |
| Interest coverage | – | 0.4× |
| Current ratio | 2.40 | 4.42 (better) |
| Altman Z-score | 2.54 (better) | 1.69 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.77% |
| Shareholder yield | 0.00% (better) | −0.77% |
| Ownership | ||
| Held by institutions | 91.0% | 94.9% |
| Held by insiders | 5.8% | 8.9% |
| Insider net buying, 12 months | −$655K (better) | −$12.1M |
| Short interest, % of float | 5.1% | 7.7% |
Go deeper
- ANGO stock overview
- ANGO income statement
- ANGO valuation and score
- AORT stock overview
- AORT income statement
- AORT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.